首页 > 最新文献

Breast disease最新文献

英文 中文
Breast reconstruction for locally advanced breast cancer previously submitted to mastectomy and an ipsilateral thoracoabdominal dermofat (ITADE) flap. 局部晚期乳腺癌的乳房重建先前提交乳房切除术和同侧胸腹真皮脂肪(ITADE)皮瓣。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220057
René Aloisio da Costa Vieira, An Wan Ching, Idam de Oliveira-Junior

Thoracoabdominal (TA) flaps are a good option for primary closure of small and medium defects after mastectomy for locally advanced breast tumours. Although they have a higher rate of necrosis than myocutaneous flaps, they can be easily performed by breast surgeons. Few studies on this procedure have been reported, and we have been unable to identify any prior publications reporting breast reconstruction with TA flaps.

胸腹皮瓣是局部晚期乳房肿瘤切除后中小型乳房缺损的良好选择。虽然它们比肌皮瓣有更高的坏死率,但它们可以很容易地被乳房外科医生实施。很少有关于该手术的研究被报道,我们也无法找到任何先前报道用TA瓣重建乳房的出版物。
{"title":"Breast reconstruction for locally advanced breast cancer previously submitted to mastectomy and an ipsilateral thoracoabdominal dermofat (ITADE) flap.","authors":"René Aloisio da Costa Vieira,&nbsp;An Wan Ching,&nbsp;Idam de Oliveira-Junior","doi":"10.3233/BD-220057","DOIUrl":"https://doi.org/10.3233/BD-220057","url":null,"abstract":"<p><p>Thoracoabdominal (TA) flaps are a good option for primary closure of small and medium defects after mastectomy for locally advanced breast tumours. Although they have a higher rate of necrosis than myocutaneous flaps, they can be easily performed by breast surgeons. Few studies on this procedure have been reported, and we have been unable to identify any prior publications reporting breast reconstruction with TA flaps.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9907779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLIS2 and CCND1 expression levels in breast cancer patients. GLIS2和CCND1在乳腺癌患者中的表达水平。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220068
Minoosh Sadeghi, Majid Gholizadeh, Neda Safataj, Mahsa Tahmasebivand, Gholamreza Mohajeri, Hajie Lotfi, Saber Yari Bostanabad, Behnaz Safar, Mansoor Salehi

Background: Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis.

Methods: In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes.

Results: The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined.

Conclusion: These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.

背景:乳腺癌(BC)是女性中最常见的癌症,近年来发病率和死亡率不断上升。不同信号通路的中断部分导致乳腺癌。因此,不同的基因通过特定的途径参与了BC肿瘤的发生。方法:本研究对50例患者GLIS2和CCND1基因的表达水平进行了检测。此外,利用芯片分析丰富了涉及上述基因的相关信号通路。结果:BC患者中Cyclin D1表达水平升高,GLIS2表达水平降低。此外,我们还确定了GLIS2和CCND1的异常表达水平与BC发展之间的关系。结论:这些观察结果有助于发现治疗进展期BC患者的新治疗靶点。
{"title":"GLIS2 and CCND1 expression levels in breast cancer patients.","authors":"Minoosh Sadeghi,&nbsp;Majid Gholizadeh,&nbsp;Neda Safataj,&nbsp;Mahsa Tahmasebivand,&nbsp;Gholamreza Mohajeri,&nbsp;Hajie Lotfi,&nbsp;Saber Yari Bostanabad,&nbsp;Behnaz Safar,&nbsp;Mansoor Salehi","doi":"10.3233/BD-220068","DOIUrl":"https://doi.org/10.3233/BD-220068","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis.</p><p><strong>Methods: </strong>In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes.</p><p><strong>Results: </strong>The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined.</p><p><strong>Conclusion: </strong>These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10024946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of risk factors and marker status in women with breast cancer in Brunei Darussalam. 文莱达鲁萨兰国妇女乳腺癌危险因素及标志物状况的研究。
Pub Date : 2023-01-01 DOI: 10.3233/BD-239001
Chieng Bing Wong, Aklimah Mustapa, Siti Nur Idayu Matusin, Muhammad Syafiq Abdullah, Andi Nilawati Usman, Mas Rina Wati Haji Abdul Hamid

Objective: To investigate the associations between breast cancer staging and body mass index (BMI), menopausal status, and family history of breast cancer, as well as to assess the expression of tumor markers in women with breast cancer in Brunei Darussalam.

Methods: A retrospective cross-sectional study was carried out at The Brunei Cancer Centre. Cases of women with breast cancer between 2000 and 2013 were retrieved from the medical records section and entered into a clinical proforma. These were reviewed and analyzed using appropriate statistical methods.

Results: Overall, the mean age at diagnosis was 53.6 years ± 9.83. The postmenopausal women had a significantly higher risk of being diagnosed with late-onset breast cancer than premenopausal women (P = 0.022). The expressions of PR (P = 0.034), Her2 (P = 0.046), and CatD (P = 0.004) were significantly different in breast cancer staging. Other factors did not have a statistically-significant association with breast cancer staging.

Conclusion: While most of the factors studied were not significantly different in breast cancer staging, our findings showed that it is recommended that high-risk women perform regular breast screening after the age of 40 years old. A future study highly appreciates comparing breast cancer risk factors among the Bruneian and Western populations.

目的:探讨文莱达鲁萨兰国乳腺癌分期与体重指数(BMI)、绝经状况、乳腺癌家族史的关系,并评估肿瘤标志物在乳腺癌妇女中的表达。方法:在文莱癌症中心进行回顾性横断面研究。从医疗记录部分检索2000年至2013年期间患乳腺癌的妇女病例,并输入临床形式表。使用适当的统计方法对这些进行了审查和分析。结果:总体而言,平均诊断年龄为53.6岁±9.83岁。绝经后妇女被诊断为晚发型乳腺癌的风险明显高于绝经前妇女(P = 0.022)。PR (P = 0.034)、Her2 (P = 0.046)、CatD (P = 0.004)在乳腺癌分期中的表达差异有统计学意义。其他因素与乳腺癌分期没有统计学上的显著关联。结论:虽然所研究的大多数因素在乳腺癌分期方面没有显著差异,但我们的研究结果表明,建议高危女性在40岁以后定期进行乳房筛查。一项未来的研究高度赞赏在文莱和西方人群中比较乳腺癌的危险因素。
{"title":"Study of risk factors and marker status in women with breast cancer in Brunei Darussalam.","authors":"Chieng Bing Wong,&nbsp;Aklimah Mustapa,&nbsp;Siti Nur Idayu Matusin,&nbsp;Muhammad Syafiq Abdullah,&nbsp;Andi Nilawati Usman,&nbsp;Mas Rina Wati Haji Abdul Hamid","doi":"10.3233/BD-239001","DOIUrl":"https://doi.org/10.3233/BD-239001","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the associations between breast cancer staging and body mass index (BMI), menopausal status, and family history of breast cancer, as well as to assess the expression of tumor markers in women with breast cancer in Brunei Darussalam.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was carried out at The Brunei Cancer Centre. Cases of women with breast cancer between 2000 and 2013 were retrieved from the medical records section and entered into a clinical proforma. These were reviewed and analyzed using appropriate statistical methods.</p><p><strong>Results: </strong>Overall, the mean age at diagnosis was 53.6 years ± 9.83. The postmenopausal women had a significantly higher risk of being diagnosed with late-onset breast cancer than premenopausal women (P = 0.022). The expressions of PR (P = 0.034), Her2 (P = 0.046), and CatD (P = 0.004) were significantly different in breast cancer staging. Other factors did not have a statistically-significant association with breast cancer staging.</p><p><strong>Conclusion: </strong>While most of the factors studied were not significantly different in breast cancer staging, our findings showed that it is recommended that high-risk women perform regular breast screening after the age of 40 years old. A future study highly appreciates comparing breast cancer risk factors among the Bruneian and Western populations.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10060047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical presentations and outcomes of young women aged <40 yrs with Ductal carcinoma in situ. 40岁以下年轻女性原位导管癌的临床表现和结果。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230018
Zhiyan Yan, Joanne Ngeow, John Allen, Geok Hoon Lim

Introduction: Ductal carcinoma in situ (DCIS) in young women is rare and not well studied. Since they do not qualify for mammographic screening, they are more likely to present with symptoms. Young women have also been associated with poorer outcomes, but it is unknown whether presentation mode affects outcome. We aimed to compare characteristics of DCIS patients <40 years of age presenting with symptoms versus those without, and determine whether presentation mode affects recurrence.

Methods: Pure DCIS patients aged <40 years were retrospectively analyzed. Clinical presentation, pathology and recurrence data were collected. Statistical analysis was performed to investigate the correlation of presentation mode with outcomes.

Results: 40 patients with 41 cases were included. The mean age at diagnosis was 32.3 years (range 17-39). 73.2% and 26.8% presented with symptoms or abnormal imaging respectively. Of the cases who presented with symptoms, 86.7%, 10.0% and 3.3% had palpable lump, nipple discharge or breast pain, respectively. The average tumor size was 22.0 mm (range 2.0-86.9) and 12.2 mm (range 3-25) for patients who presented with symptoms and non-symptomatic group, respectively. Cases presenting with symptoms were statistically associated with higher grade (p = 0.0090). On median follow-up of 85 months, there were 3 (7.3%) recurrences, which were not statistically associated with presentation mode.

Conclusion: Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.

引言:年轻女性的导管原位癌(DCIS)很少见,研究也不充分。由于他们没有资格接受乳房X光检查,他们更有可能出现症状。年轻女性也与较差的结果有关,但尚不清楚表现模式是否会影响结果。我们旨在比较DCIS患者的特征。方法:年龄为纯DCIS患者。结果:纳入40例患者,41例。诊断时的平均年龄为32.3岁(范围17-39岁)。73.2%和26.8%的患者出现症状或影像学异常。在出现症状的病例中,86.7%、10.0%和3.3%的患者有可触摸的肿块、乳头分泌物或乳房疼痛。有症状组和无症状组的平均肿瘤大小分别为22.0 mm(范围2.0-86.9)和12.2 mm(范围3-25)。有症状的病例在统计学上与更高的分级相关(p=0.0090)。在85个月的中位随访中,有3例(7.3%)复发,与表现模式没有统计学相关性。结论:DCIS的年轻女性往往表现出症状,其中乳腺肿块是最常见的症状。与无症状患者相比,有症状的患者往往与III级肿瘤相关。在长期随访中,表现方式与复发无统计学相关性。
{"title":"Clinical presentations and outcomes of young women aged <40 yrs with Ductal carcinoma in situ.","authors":"Zhiyan Yan,&nbsp;Joanne Ngeow,&nbsp;John Allen,&nbsp;Geok Hoon Lim","doi":"10.3233/BD-230018","DOIUrl":"10.3233/BD-230018","url":null,"abstract":"<p><strong>Introduction: </strong>Ductal carcinoma in situ (DCIS) in young women is rare and not well studied. Since they do not qualify for mammographic screening, they are more likely to present with symptoms. Young women have also been associated with poorer outcomes, but it is unknown whether presentation mode affects outcome. We aimed to compare characteristics of DCIS patients <40 years of age presenting with symptoms versus those without, and determine whether presentation mode affects recurrence.</p><p><strong>Methods: </strong>Pure DCIS patients aged <40 years were retrospectively analyzed. Clinical presentation, pathology and recurrence data were collected. Statistical analysis was performed to investigate the correlation of presentation mode with outcomes.</p><p><strong>Results: </strong>40 patients with 41 cases were included. The mean age at diagnosis was 32.3 years (range 17-39). 73.2% and 26.8% presented with symptoms or abnormal imaging respectively. Of the cases who presented with symptoms, 86.7%, 10.0% and 3.3% had palpable lump, nipple discharge or breast pain, respectively. The average tumor size was 22.0 mm (range 2.0-86.9) and 12.2 mm (range 3-25) for patients who presented with symptoms and non-symptomatic group, respectively. Cases presenting with symptoms were statistically associated with higher grade (p = 0.0090). On median follow-up of 85 months, there were 3 (7.3%) recurrences, which were not statistically associated with presentation mode.</p><p><strong>Conclusion: </strong>Young women with DCIS tend to present with symptoms, with breast lump as the commonest symptom. Symptomatic patients tend to be associated with grade III tumours, compared to non-symptomatic patients. On long-term follow-up, mode of presentation was not statistically associated with recurrence.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41092631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast amyloidosis associated with Sjögren syndrome: A diagnostic pitfall in breast pathology. 与斯约格伦综合征相关的乳腺淀粉样变性:乳腺病理诊断中的一个陷阱。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230006
Oumeima Khaldi, Montassar Ghalleb, Amani Jallali, Insaf Fenniche, Mehdi Somai, Fatma Daoud, Fatma Boussema, Salma Kammoun, Khadija Hamza, Med Ali Ayadi, Tarek Dhieb

Background: Amyloidosis is an uncommon disorder characterized by the extracellular deposition of amorphous and insoluble proteins in an abnormal fibrillary configuration. Mammary amyloidosis is an unusual and easily overlooked diagnosis with an ambivalent presentation that could mimic breast cancer.

Case report: We here report the case of 60-year-old Caucasian woman who presented to our surgical oncology department for clinically and radiologically suspicious breast mass. A fine needle biopsy was irrelevant, so we performed a lumpectomy. Final histology revealed an amyloid deposit and further workup was consistent with nodular cutaneous and breast AL amyloidosis associated with Sjögren's syndrome.

Conclusion: Although rare, an awareness of the clinicopathologic characteristics of this easily overlooked entity is of great importance for breast surgeons.

背景:淀粉样变性是一种不常见的疾病,其特征是无定形和不溶性蛋白质在细胞外沉积成异常的纤维状结构。乳腺淀粉样变性是一种不常见且容易被忽视的诊断,其表现不明确,可能与乳腺癌相似:病例报告:我们在此报告了一例 60 岁的白种女性病例,她因临床和影像学上可疑的乳房肿块而到肿瘤外科就诊。细针穿刺活检并不相关,因此我们进行了肿块切除术。最后的组织学检查发现了淀粉样沉积物,进一步检查结果与结节性皮肤和乳腺AL淀粉样变性伴斯约格伦综合征一致:结论:虽然这种病很少见,但了解这种容易被忽视的疾病的临床病理特征对乳腺外科医生来说非常重要。
{"title":"Breast amyloidosis associated with Sjögren syndrome: A diagnostic pitfall in breast pathology.","authors":"Oumeima Khaldi, Montassar Ghalleb, Amani Jallali, Insaf Fenniche, Mehdi Somai, Fatma Daoud, Fatma Boussema, Salma Kammoun, Khadija Hamza, Med Ali Ayadi, Tarek Dhieb","doi":"10.3233/BD-230006","DOIUrl":"https://doi.org/10.3233/BD-230006","url":null,"abstract":"<p><strong>Background: </strong>Amyloidosis is an uncommon disorder characterized by the extracellular deposition of amorphous and insoluble proteins in an abnormal fibrillary configuration. Mammary amyloidosis is an unusual and easily overlooked diagnosis with an ambivalent presentation that could mimic breast cancer.</p><p><strong>Case report: </strong>We here report the case of 60-year-old Caucasian woman who presented to our surgical oncology department for clinically and radiologically suspicious breast mass. A fine needle biopsy was irrelevant, so we performed a lumpectomy. Final histology revealed an amyloid deposit and further workup was consistent with nodular cutaneous and breast AL amyloidosis associated with Sjögren's syndrome.</p><p><strong>Conclusion: </strong>Although rare, an awareness of the clinicopathologic characteristics of this easily overlooked entity is of great importance for breast surgeons.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of tumor size, histopathological grade, and molecular subtype of breast cancer at a single center study. 单中心研究中乳腺癌肿瘤大小、组织病理分级和分子亚型的比较
Pub Date : 2023-01-01 DOI: 10.3233/BD-239000
Awaluddin Awaluddin, John Pieter, Elridho Sampepajung, Salman Ardi Syamsu, Nilam Smaradhania, Firdaus Hamid, Prihantono Prihantono, Sachraswaty R Laidding, Muhammad Ihwan Kusuma, Muhammad Faruk

Background: Breast cancer (BC) is the second most frequent cancer-related death among women worldwide. Factors influencing BC patients' survival include histopathological grade, histopathological type, stage, hormonal receptors, and number of mitotic images.

Objective: To compare the tumor size, histopathological grade, and molecular type of BC patients.

Methods: This was an observational analytic retrospective study. The population was BC patients at Dr. Wahidin Sudirohusodo Hospital from 2017 to 2021. The Kruskal-Wallis test was used to compare statistically between tumor size, histopathological grade, and molecular subtype. Significance was set at p < 0.05.

Results: The study included 784 patients. Most were aged 50-59 years (34.8%), with tumor size 4c (37.0%) and moderate grade (66.1%), and the most common molecular subtype was luminal A (34.2%). Bivariate analysis using the Kruskal-Wallis test found no significant difference in molecular subtypes based on tumor size (p = 0.079), but significant differences existed in molecular subtype by histopathological grade (p = 0.005) and tumor size by histopathological grade (p < 0.001).

Conclusions: Significant differences existed between histopathological grade by tumor size and molecular subtype. Early diagnosis and prompt treatment of BC patients are important to prevent morbidity and mortality.

背景:乳腺癌(BC)是全世界女性中第二常见的癌症相关死亡。影响BC患者生存的因素包括组织病理分级、组织病理类型、分期、激素受体和有丝分裂成像次数。目的:比较BC患者的肿瘤大小、组织病理分级和分子分型。方法:观察性分析回顾性研究。人群为2017年至2021年在Dr. Wahidin Sudirohusodo医院就诊的BC患者。采用Kruskal-Wallis检验对肿瘤大小、组织病理分级和分子亚型进行统计学比较。结果:研究纳入784例患者。大多数患者年龄在50-59岁(34.8%),肿瘤大小为4c(37.0%),中度(66.1%),最常见的分子亚型为腔内A(34.2%)。采用Kruskal-Wallis检验进行双变量分析发现,基于肿瘤大小的分子亚型差异无统计学意义(p = 0.079),而基于组织病理分级的分子亚型差异有统计学意义(p = 0.005),基于组织病理分级的肿瘤大小差异有统计学意义(p)。结论:基于肿瘤大小和分子亚型的组织病理分级存在统计学意义。早期诊断和及时治疗BC患者是重要的,以防止发病率和死亡率。
{"title":"Comparison of tumor size, histopathological grade, and molecular subtype of breast cancer at a single center study.","authors":"Awaluddin Awaluddin,&nbsp;John Pieter,&nbsp;Elridho Sampepajung,&nbsp;Salman Ardi Syamsu,&nbsp;Nilam Smaradhania,&nbsp;Firdaus Hamid,&nbsp;Prihantono Prihantono,&nbsp;Sachraswaty R Laidding,&nbsp;Muhammad Ihwan Kusuma,&nbsp;Muhammad Faruk","doi":"10.3233/BD-239000","DOIUrl":"https://doi.org/10.3233/BD-239000","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the second most frequent cancer-related death among women worldwide. Factors influencing BC patients' survival include histopathological grade, histopathological type, stage, hormonal receptors, and number of mitotic images.</p><p><strong>Objective: </strong>To compare the tumor size, histopathological grade, and molecular type of BC patients.</p><p><strong>Methods: </strong>This was an observational analytic retrospective study. The population was BC patients at Dr. Wahidin Sudirohusodo Hospital from 2017 to 2021. The Kruskal-Wallis test was used to compare statistically between tumor size, histopathological grade, and molecular subtype. Significance was set at p < 0.05.</p><p><strong>Results: </strong>The study included 784 patients. Most were aged 50-59 years (34.8%), with tumor size 4c (37.0%) and moderate grade (66.1%), and the most common molecular subtype was luminal A (34.2%). Bivariate analysis using the Kruskal-Wallis test found no significant difference in molecular subtypes based on tumor size (p = 0.079), but significant differences existed in molecular subtype by histopathological grade (p = 0.005) and tumor size by histopathological grade (p < 0.001).</p><p><strong>Conclusions: </strong>Significant differences existed between histopathological grade by tumor size and molecular subtype. Early diagnosis and prompt treatment of BC patients are important to prevent morbidity and mortality.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection? 芳香酶抑制剂治疗绝经后乳腺癌患者的骨修饰剂:超越骨保护?
Pub Date : 2023-01-01 DOI: 10.3233/BD-220014
Andrea Villasco, Carola Minella, Valentina Elisabetta Bounous, Roberta Rosso, Nicoletta Biglia

Estrogen-receptor positive tumours represent the majority of breast cancers in postmenopausal women. Adjuvant endocrine therapy with aromatase inhibitors (AIs), continued for up to 10 years in high-risk patients, reduces by 40% the risk of recurrence. However, this therapy, among other side effects, is burdened with a higher incidence of osteoporotic bone fractures. To date, both bisphosphonates and denosumab are recognized as first-line drugs in the primary prevention of osteoporotic fractures in patients treated with AIs. They have demonstrated their effectiveness in increasing bone mineral density and in reducing the incidence of fractures, but they have also been shown to improve disease free survival (DFS).

雌激素受体阳性肿瘤占绝经后妇女乳腺癌的大多数。在高危患者中使用芳香酶抑制剂(AIs)进行辅助内分泌治疗长达10年,可减少40%的复发风险。然而,除其他副作用外,这种疗法还具有较高的骨质疏松性骨折发生率。迄今为止,双膦酸盐和地诺单抗都被认为是AIs患者骨质疏松性骨折一级预防的一线药物。它们已被证明在增加骨密度和减少骨折发生率方面有效,但它们也被证明可以提高无病生存率(DFS)。
{"title":"Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?","authors":"Andrea Villasco,&nbsp;Carola Minella,&nbsp;Valentina Elisabetta Bounous,&nbsp;Roberta Rosso,&nbsp;Nicoletta Biglia","doi":"10.3233/BD-220014","DOIUrl":"https://doi.org/10.3233/BD-220014","url":null,"abstract":"<p><p>Estrogen-receptor positive tumours represent the majority of breast cancers in postmenopausal women. Adjuvant endocrine therapy with aromatase inhibitors (AIs), continued for up to 10 years in high-risk patients, reduces by 40% the risk of recurrence. However, this therapy, among other side effects, is burdened with a higher incidence of osteoporotic bone fractures. To date, both bisphosphonates and denosumab are recognized as first-line drugs in the primary prevention of osteoporotic fractures in patients treated with AIs. They have demonstrated their effectiveness in increasing bone mineral density and in reducing the incidence of fractures, but they have also been shown to improve disease free survival (DFS).</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10753077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases. 一种有争议的乳腺癌ER阴性PR阳性分子亚型——附两例报告。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230039
Smita Chandra, Sanya Bhasin, Sunil Saini

ER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.

ER-/PR+是一种有争议的亚型,尚未被正式认定为乳腺癌的分子亚型。很少有研究得出结论认为这种亚型不存在,是由于技术错误,然而,相比之下,其他研究认为它是一个对治疗和临床结果有不同反应的独特实体。了解这种亚型是否表现出任何明显的组织形态学特征或预后也很重要。因此,目前报道了两例有争议的ER-/PR+亚型癌症,这两例都表现出神经内分泌分化。
{"title":"A controversial ER negative PR positive molecular subtype of breast carcinoma-Report of two cases.","authors":"Smita Chandra,&nbsp;Sanya Bhasin,&nbsp;Sunil Saini","doi":"10.3233/BD-230039","DOIUrl":"10.3233/BD-230039","url":null,"abstract":"<p><p>ER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41100241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rapidly growing fibroadenoma in a pregnant woman: A case report. 孕妇快速生长的纤维腺瘤:一例报告。
Pub Date : 2023-01-01 DOI: 10.3233/BD-230030
I M Brouwer de Koning, H C van Heusden, S J J Mol, M L Rots, W A Draaisma, K Bosscha

Background: Fibroadenomas are the most common benign breast lesions in women. They present as a unilateral mass and can rapidly enlarge in size through hormonal changes. Fibroadenomas could be classified as small or giant, and as simple or complex. They are classified as 'giant' when the size exceeds 5 cm and/or weight 500 gram; and as 'complex' if one of the following characteristics is present: cysts with a size >3 mm, epithelial calcifications, sclerosing adenosis and papillary apocrine metaplasia. Giant fibroadenomas can cause compression of surrounding breast tissue or breast asymmetry, requiring surgical excision in order to preserve a normal breast shape.

Case: A 26-year-old pregnant woman was referred with a palpable mass of her right breast. The mass rapidly increased in size to a diameter of 13 cm during the second trimester of her pregnancy. A tru-cut biopsy confirmed a fibroadenoma. The rapid growth and compression of normal breast tissues indicated a lumpectomy during her pregnancy. The mass was easily excised without any consequences for the pregnancy. Pathological examination showed a complex giant fibroadenoma.

Conclusion: A unique case of a pregnant woman with rapid progression of a fibroadenoma that met the criteria of a complex and giant fibroadenoma, was presented. This case emphasizes the importance of timely surgical intervention, even during pregnancy, to prevent permanent breast tissue damage.

背景:纤维腺瘤是女性乳腺最常见的良性病变。它们表现为单侧肿块,并可通过激素变化迅速增大。纤维腺瘤可分为小腺瘤或巨大腺瘤,也可分为简单腺瘤或复杂腺瘤。当体型超过5厘米和/或重量超过500克时,它们被归类为“巨人”;如果存在以下特征之一,则称为“复杂”:大小>3 mm的囊肿、上皮钙化、硬化性腺病和乳头状顶泌化生。巨大的纤维腺瘤会导致周围乳房组织受压或乳房不对称,需要手术切除才能保持正常的乳房形状。病例:一名26岁孕妇被转诊,其右乳房有明显肿块。在她怀孕的中期,肿块的大小迅速增加到直径13厘米。tru-cut活组织检查证实为纤维腺瘤。正常乳房组织的快速生长和压迫表明她在怀孕期间进行了肿块切除术。肿块很容易切除,对妊娠没有任何影响。病理检查显示为复杂的巨大纤维腺瘤。结论:报告了一例独特的孕妇,其纤维腺瘤进展迅速,符合复杂巨大纤维腺瘤的标准。该病例强调了及时手术干预的重要性,即使是在怀孕期间,也要防止永久性乳房组织损伤。
{"title":"A rapidly growing fibroadenoma in a pregnant woman: A case report.","authors":"I M Brouwer de Koning,&nbsp;H C van Heusden,&nbsp;S J J Mol,&nbsp;M L Rots,&nbsp;W A Draaisma,&nbsp;K Bosscha","doi":"10.3233/BD-230030","DOIUrl":"https://doi.org/10.3233/BD-230030","url":null,"abstract":"<p><strong>Background: </strong>Fibroadenomas are the most common benign breast lesions in women. They present as a unilateral mass and can rapidly enlarge in size through hormonal changes. Fibroadenomas could be classified as small or giant, and as simple or complex. They are classified as 'giant' when the size exceeds 5 cm and/or weight 500 gram; and as 'complex' if one of the following characteristics is present: cysts with a size >3 mm, epithelial calcifications, sclerosing adenosis and papillary apocrine metaplasia. Giant fibroadenomas can cause compression of surrounding breast tissue or breast asymmetry, requiring surgical excision in order to preserve a normal breast shape.</p><p><strong>Case: </strong>A 26-year-old pregnant woman was referred with a palpable mass of her right breast. The mass rapidly increased in size to a diameter of 13 cm during the second trimester of her pregnancy. A tru-cut biopsy confirmed a fibroadenoma. The rapid growth and compression of normal breast tissues indicated a lumpectomy during her pregnancy. The mass was easily excised without any consequences for the pregnancy. Pathological examination showed a complex giant fibroadenoma.</p><p><strong>Conclusion: </strong>A unique case of a pregnant woman with rapid progression of a fibroadenoma that met the criteria of a complex and giant fibroadenoma, was presented. This case emphasizes the importance of timely surgical intervention, even during pregnancy, to prevent permanent breast tissue damage.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast lymphoma: General review. 乳腺淋巴瘤:综述。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220051
Emad M N Rezkallah, Andrew Elsaify, Su M M Tin, Debdeep Dey, Wael M Elsaify

Background: Lymphoma of the breast can be classified as either primary breast lymphoma (PBL) or secondary to systemic lymphoma (SBL). PBL is a rare disease with Diffuse Large B cell Lymphomas (DLBCL) being the most common subtype.

Objectives: In the current study, we represented eleven cases diagnosed with breast lymphoma in our trust; two of them had PBL and nine had SBL. We focused mainly on the clinical presentation, diagnosis, management and outcomes.

Methods: We did this retrospective review for all breast lymphoma patients who were diagnosed in our trust during the periods from 2011-2022. Patients' data were obtained from the hospital recording system. We followed up these patients thus far to identify the outcome of treatment in each patient.

Results: Eleven patients were included in our review. All patients were females. Average age of diagnosis was 66.1 ± 13 years of age. Eight patients were diagnosed with DLBCL, two patients were diagnosed with follicular lymphomas, and the last one had lymphoplasmacytic lymphoma. Chemotherapy +∕- radiotherapy was the standard treatment regimen in all patients. Four patients passed away within one year of chemotherapy, five patients achieved complete remission, one patient had two relapses and is still under treatment, while the last patient was diagnosed recently and still awaiting treatment.

Conclusion: Primary breast lymphoma is an aggressive disease. The treatment for PBL is mainly systemic with chemoradiotherapy. The role of surgery is now limited to the diagnosis of the disease. Early diagnosis and proper treatment are crucial for the management of such cases.

背景:乳腺淋巴瘤可分为原发性乳腺淋巴瘤(PBL)和继发性全身淋巴瘤(SBL)。原发性乳腺淋巴瘤是一种罕见疾病,弥漫大 B 细胞淋巴瘤(DLBCL)是最常见的亚型:在本研究中,有 11 例乳腺淋巴瘤患者在我院确诊,其中 2 例为 PBL,9 例为 SBL。我们主要关注临床表现、诊断、处理和结果:我们对 2011 年至 2022 年期间在本医院确诊的所有乳腺淋巴瘤患者进行了回顾性研究。患者数据来自医院记录系统。我们对这些患者进行了随访,以确定每位患者的治疗结果:有 11 名患者被纳入我们的研究范围。所有患者均为女性。平均确诊年龄为(66.1 ± 13)岁。八名患者被诊断为DLBCL,两名患者被诊断为滤泡性淋巴瘤,最后一名患者为淋巴浆细胞性淋巴瘤。化疗+∕-放疗是所有患者的标准治疗方案。四名患者在化疗后一年内去世,五名患者获得完全缓解,一名患者两次复发,目前仍在治疗中,最后一名患者最近才确诊,仍在等待治疗:结论:原发性乳腺淋巴瘤是一种侵袭性疾病。结论:原发性乳腺淋巴瘤是一种侵袭性疾病。手术的作用目前仅限于疾病的诊断。早期诊断和适当治疗对此类病例的治疗至关重要。
{"title":"Breast lymphoma: General review.","authors":"Emad M N Rezkallah, Andrew Elsaify, Su M M Tin, Debdeep Dey, Wael M Elsaify","doi":"10.3233/BD-220051","DOIUrl":"10.3233/BD-220051","url":null,"abstract":"<p><strong>Background: </strong>Lymphoma of the breast can be classified as either primary breast lymphoma (PBL) or secondary to systemic lymphoma (SBL). PBL is a rare disease with Diffuse Large B cell Lymphomas (DLBCL) being the most common subtype.</p><p><strong>Objectives: </strong>In the current study, we represented eleven cases diagnosed with breast lymphoma in our trust; two of them had PBL and nine had SBL. We focused mainly on the clinical presentation, diagnosis, management and outcomes.</p><p><strong>Methods: </strong>We did this retrospective review for all breast lymphoma patients who were diagnosed in our trust during the periods from 2011-2022. Patients' data were obtained from the hospital recording system. We followed up these patients thus far to identify the outcome of treatment in each patient.</p><p><strong>Results: </strong>Eleven patients were included in our review. All patients were females. Average age of diagnosis was 66.1 ± 13 years of age. Eight patients were diagnosed with DLBCL, two patients were diagnosed with follicular lymphomas, and the last one had lymphoplasmacytic lymphoma. Chemotherapy +∕- radiotherapy was the standard treatment regimen in all patients. Four patients passed away within one year of chemotherapy, five patients achieved complete remission, one patient had two relapses and is still under treatment, while the last patient was diagnosed recently and still awaiting treatment.</p><p><strong>Conclusion: </strong>Primary breast lymphoma is an aggressive disease. The treatment for PBL is mainly systemic with chemoradiotherapy. The role of surgery is now limited to the diagnosis of the disease. Early diagnosis and proper treatment are crucial for the management of such cases.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1